touchIN CONVERSATION
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection
- Downloads including slides are available for this activity in the Toolkit
Learning Objectives
After watching this activity, participants should be better able to:
- Discuss the rationale for using PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer
- Identify patients who may benefit from a PARP inhibitor in the first-line maintenance setting
- Describe the key factors that can inform selection of the most appropriate PARP inhibitor for each patient
Overview
In this activity, gynaecologic oncology specialists Prof. Nicoletta Colombo and Dr Natalia R Gómez-Hidalgo discuss three key topics relating to PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer – rationale for use, which patients may particularly benefit, and key factors informing PARP inhibitor selection. Discussion on these themes is based on questions posed by healthcare professionals involved in the care of patients with ovarian cancer.
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.
Claim Credit- Downloads including slides are available for this activity in the Toolkit
You may also be interested in...
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights